[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2023131872A3 - Rectal administration techniques - Google Patents

Rectal administration techniques Download PDF

Info

Publication number
WO2023131872A3
WO2023131872A3 PCT/IB2023/050001 IB2023050001W WO2023131872A3 WO 2023131872 A3 WO2023131872 A3 WO 2023131872A3 IB 2023050001 W IB2023050001 W IB 2023050001W WO 2023131872 A3 WO2023131872 A3 WO 2023131872A3
Authority
WO
WIPO (PCT)
Prior art keywords
rectal administration
virus
administration techniques
pathogen
subject
Prior art date
Application number
PCT/IB2023/050001
Other languages
French (fr)
Other versions
WO2023131872A2 (en
Inventor
Noa BARTOV
Original Assignee
Bartov Noa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bartov Noa filed Critical Bartov Noa
Publication of WO2023131872A2 publication Critical patent/WO2023131872A2/en
Publication of WO2023131872A3 publication Critical patent/WO2023131872A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A wipe (40B), formulated for rectal administration, and comprising a respiratory virus, such as an influenza virus or a coronavirus. Other embodiments are also described, in some applications, a method includes identifying a human subject to be inoculated with (e.g., immunized against) a non-gastrointestinal pathogen, e.g., a respiratory virus or a central nervous system (CNS) virus, and then rectally inoculating (e.g., infecting) the subject with the pathogen.
PCT/IB2023/050001 2022-01-04 2023-01-01 Rectal administration techniques WO2023131872A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263296231P 2022-01-04 2022-01-04
US63/296,231 2022-01-04

Publications (2)

Publication Number Publication Date
WO2023131872A2 WO2023131872A2 (en) 2023-07-13
WO2023131872A3 true WO2023131872A3 (en) 2023-10-26

Family

ID=87073337

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2023/050001 WO2023131872A2 (en) 2022-01-04 2023-01-01 Rectal administration techniques

Country Status (1)

Country Link
WO (1) WO2023131872A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190105261A1 (en) * 2017-10-11 2019-04-11 Illustris Pharmaceuticals, Inc. Methods and compositions for topical delivery
US20200046826A1 (en) * 2009-03-27 2020-02-13 Academia Sinica Methods and compositions for immunization against virus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200046826A1 (en) * 2009-03-27 2020-02-13 Academia Sinica Methods and compositions for immunization against virus
US20190105261A1 (en) * 2017-10-11 2019-04-11 Illustris Pharmaceuticals, Inc. Methods and compositions for topical delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CROWLEY-NOWICK P. A.; BELL M. C.; BROCKWELL R.; EDWARDS R. P.; CHEN S.; PARTRIDGE E. E.; MESTECKY J.: "Rectal Immunization for Induction of Specific Antibody in the Genital Tract of Women", JOURNAL OF CLINICAL IMMUNOLOGY, KLUWER ACADEMIC PUBLISHERS, NEW YORK, vol. 17, no. 5, 1 September 1997 (1997-09-01), New York , pages 370 - 379, XP037122790, ISSN: 0271-9142, DOI: 10.1023/A:1027312223474 *

Also Published As

Publication number Publication date
WO2023131872A2 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
AU4358701A (en) Methods of preventing and treating respiratory viral infeciton using immunomodulatory polynucleotide sequences
DK1618889T3 (en) Influenza vaccine
MY163972A (en) Attenuated recombinant newcastle disease virus and vaccine containing the same
JP2004509903A5 (en)
MY159500A (en) Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
MX341842B (en) Influenza viruses able to infect canids, uses thereof.
WO2018140766A3 (en) Porcine coronavirus vaccines
CO2020009283A2 (en) Wireless device, network node and methods performed in this way
RU2020119271A (en) VACCINE FOR PROTECTION AGAINST STREPTOCOCCUS SUIS
WO2018158306A8 (en) Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
RU2010129770A (en) VACCINE AGAINST INFLUENZA AND METHOD FOR PRODUCING IT
WO2023131872A3 (en) Rectal administration techniques
WO2012074881A3 (en) Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
Vizcaíno et al. Biology and genetics of the Brucella outer membrane
Parrella et al. Plantago asiatica mosaic virus found in protected crops of lily hybrids in Southern Italy
Tao et al. Studies of coltivirus in China
EP4120908A4 (en) Methods, database and system for use with viral infection
Jin et al. Transmission network flexible planning based on connection number model.
PH12020550687A1 (en) Single strain dysentery vaccine
WO2008030619A3 (en) Pcr-based genotyping
Sheikh et al. COVID-19: Questionable seasonality
MY190074A (en) A monovalent vaccine formulation and a method for preparation thereof
TW200710224A (en) Attenuated avian infectious bronchitis virus vaccines
WO2024163949A3 (en) Pediatric sars-cov-2 antibodies and uses thereof
Langeois et al. Efficacy of the H120 infectious bronchitis virus vaccine against a Nigerian IBADAN06 virus in the chicken model

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23737233

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE